A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline DOI Creative Commons
Joseph Miller, Michael R. Rose,

Jonathan Roell

et al.

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18

Published: Dec. 24, 2024

Recent successes in the identification of biomarkers and therapeutic targets for diagnosing managing neurological diseases underscore critical need cutting-edge biobanks conduct high-caliber translational neuroscience research. Biobanks dedicated to disorders are particularly timely, given increasing prevalence disability among rising aging population. Translational research focusing on central nervous system (CNS) poses distinct challenges due limited accessibility CNS tissue pre-mortem. Nevertheless, technological breakthroughs, including single-cell single-nucleus methodologies, offer unprecedented insights into pathophysiology using minimal input such as cerebrospinal fluid (CSF) cells brain biopsies. Moreover, assays designed detect factors that released by resident diffuse CSF and/or bloodstream (such neurofilament light chain [NfL], glial fibrillar acidic protein [GFAP] amyloid beta peptides), systemic cross blood–brain barrier target CNS-specific molecules (e.g., autoantibodies bind either NMDA receptor [NMDAR] or myelin oligodendrocyte glycoprotein [MOG]), increasingly deployed clinical practice. This review provides an overview current biobanking practices discusses ongoing biomarker discovery. Additionally, it outlines a rapid consenting processing pipeline ensuring fresh paired blood specimens sequencing might more accurately reflect vivo pathways. In summary, augmenting biobank rigor establishing innovative pipelines patient samples will undoubtedly accelerate discovery disorders.

Language: Английский

A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline DOI Creative Commons
Joseph Miller, Michael R. Rose,

Jonathan Roell

et al.

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18

Published: Dec. 24, 2024

Recent successes in the identification of biomarkers and therapeutic targets for diagnosing managing neurological diseases underscore critical need cutting-edge biobanks conduct high-caliber translational neuroscience research. Biobanks dedicated to disorders are particularly timely, given increasing prevalence disability among rising aging population. Translational research focusing on central nervous system (CNS) poses distinct challenges due limited accessibility CNS tissue pre-mortem. Nevertheless, technological breakthroughs, including single-cell single-nucleus methodologies, offer unprecedented insights into pathophysiology using minimal input such as cerebrospinal fluid (CSF) cells brain biopsies. Moreover, assays designed detect factors that released by resident diffuse CSF and/or bloodstream (such neurofilament light chain [NfL], glial fibrillar acidic protein [GFAP] amyloid beta peptides), systemic cross blood–brain barrier target CNS-specific molecules (e.g., autoantibodies bind either NMDA receptor [NMDAR] or myelin oligodendrocyte glycoprotein [MOG]), increasingly deployed clinical practice. This review provides an overview current biobanking practices discusses ongoing biomarker discovery. Additionally, it outlines a rapid consenting processing pipeline ensuring fresh paired blood specimens sequencing might more accurately reflect vivo pathways. In summary, augmenting biobank rigor establishing innovative pipelines patient samples will undoubtedly accelerate discovery disorders.

Language: Английский

Citations

0